Policy & Regulation
Zucara Therapeutics commences ZT-01 phase 1b trial
29 July 2021 -

Zucara Therapeutics Inc, a Canada-based diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycaemia (low blood glucose levels), announced on Wednesday that it has dosed the first patients in its Phase 1b trial of ZT-01.

The study is to enrol around 25 Type 1 diabetes patients who will undergo a hypoglycaemic clamp procedure including administration of either ZT-01 or placebo.

The main aim of the study is to assess the effect of the product on glucagon levels. Other study objectives include further assessment of the safety and tolerability of the product and assessment of symptoms and other hormones related to hypoglycaemia. Top line results are likely to be revealed in the first quarter of 2022. The study is to be conducted at LMC Manna Research, providing phase one to four clinical trial services with a specialised focus on diabetes and general endocrine disorders. The company has already completed a single and multiple ascending dose Phase one trial, in which the product was safe and well-tolerated.